Physician profile
Curtis L Chen
NPI 1083334619
$68,772.08
in general payments reported to CMS, 2019-2025
27 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $2,951 · 2024: $10K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $19K · Food and Beverage: $14K · Travel and Lodging: $12K · Honoraria: $2,100 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,050.00 |
| Consulting Fee | $18,777.50 |
| Food and Beverage | $13,812.99 |
| Travel and Lodging | $11,609.90 |
| Honoraria | $2,100.00 |
| Education | $247.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18,149.03 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $16,302.36 | 2024-2025 | Zoryve |
| Organon LLC | $10,000.19 | 2025 | Vtama |
| Kowa Pharmaceuticals America, INC. | $7,631.74 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $3,603.44 | 2023-2024 | Vtama |
| Leo Pharma INC. | $2,277.93 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $2,158.82 | 2023-2025 | Opzelura |
| Abbvie INC. | $1,972.25 | 2023-2025 | |
| Ucb, INC. | $1,419.60 | 2023-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $1,000.00 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $966.61 | 2023-2024 | Siliq, Cabtreo, Targretin |
| Janssen Biotech, INC. | $835.12 | 2023-2025 | Tremfya |
| Pfizer INC. | $511.94 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $402.02 | 2023-2025 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $336.71 | 2023-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $235.32 | 2022-2025 | Cosentyx |
| E.R. Squibb & Sons, L.L.C. | $206.72 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $176.20 | 2023-2024 | |
| Journey Medical Corporation | $127.99 | 2023 | |
| Botanix Sb INC | $126.39 | 2025 | Sofdra |
| Lilly USA, LLC | $92.73 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Helsinn Therapeutics (U.S.), INC. | $75.94 | 2023 | Valchlor |
| Amgen INC. | $65.77 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.75 | 2022 | |
| Cipher Pharmaceuticals US LLC | $19.50 | 2025 | Spinosad, Natroba |
| Regeneron Pharmaceuticals, INC. | $16.76 | 2024 | Dupixent |
| Phadia US INC. | $15.25 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.